Literature DB >> 32141346

Analysis of Choroidal Thickness in Children with Congenital Aniridia.

Hui Chen1, Xiaohang Wu1, Xiaoyan Li1, Jingjing Chen1, Zhuoling Lin1, Weirong Chen1, Haotian Lin1.   

Abstract

Purpose: To evaluate the choroidal thickness (CT) in children with congenital aniridia in comparison with age-matched controls.
Methods: This was a cross-sectional, observational study that included 64 eyes of 32 children with congenital aniridia (aged 5-12 years) and 80 eyes of 40 healthy subjects who were age-matched. In all subjects, subfoveal choroidal thickness (SFCT) was assessed at 750-μm intervals from the fovea to 1.5 mm in the temporal and nasal directions with spectral-domain optical coherence tomography (SD-OCT).
Results: The mean SFCT was 207.67 ± 30.99 µm in the aniridic eyes. This SFCT was significantly thinner than that in control eyes (288.55 ± 30.06 µm) (P < .001). The SFCTs at 1.5 mm and 0.75 mm intervals in the temporal and nasal directions from the fovea were also significantly thinner in eyes with aniridia than control eyes (P < .001).There was a significant negative correlation between the SFCT and axial length in eyes with aniridia (B = -10.60, 95%CI = -19.31~-1.89, P = .017). Conclusions: The subfoveal and parafoveal CTs were significantly thinner in eyes with congenital aniridia than in control eyes. These choroidal changes could open up a new way for the research related to the pathophysiology of congenital aniridia.

Entities:  

Keywords:  Congenital aniridia; choroidal thickness; optical coherence tomography (OCT)

Year:  2020        PMID: 32141346     DOI: 10.1080/02713683.2020.1736309

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  1 in total

Review 1.  Clinical and molecular aspects of congenital aniridia - A review of current concepts.

Authors:  Shailja Tibrewal; Ria Ratna; Abha Gour; Sumita Agarkar; Suneeta Dubey; Suma Ganesh; Ramesh Kekunnaya; Virender Sangwan; Yutao Liu; Vanita Vanita
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.